{"entity":{"id":"kyoto-university-hospital","kind":"institution","name":"Kyoto University Hospital","aka":["京都大学医学部附属病院","Kyoto University Cancer Center"],"tldr":"The university where Tasuku Honjo discovered PD-1 and Shinya Yamanaka created iPS cells; its hospital leads Japanese immunotherapy and cell therapy research.","summary":"Kyoto University Hospital is the clinical arm of a university whose Graduate School of Medicine produced two Nobel prizes relevant to cancer: Tasuku Honjo's discovery of PD-1 (2018 Nobel), which led to nivolumab, and Shinya Yamanaka's induced pluripotent stem cells (2012 Nobel), now the basis of iPS-derived NK and T-cell products from the Center for iPS Cell Research and Application. The hospital runs Japan's largest early-phase immunotherapy programme with Ono Pharmaceutical partnerships, a leading haematology and transplant department, hepatobiliary and pancreatic surgery, and a core institution role in JCOG and WJOG trials. Its Institute for Advancement of Clinical and Translational Science supports investigator-initiated trials, and Kyoto's cancer research includes the Kyoto Prize-associated work on immune checkpoint biology.","asOf":"2026-09-09","links":[{"label":"Kyoto University Hospital","url":"https://www.kuhp.kyoto-u.ac.jp"},{"label":"Center for iPS Cell Research and Application","url":"https://www.cira.kyoto-u.ac.jp"},{"label":"Kyoto University Graduate School of Medicine","url":"https://www.med.kyoto-u.ac.jp"}],"tags":[],"related":["jsmo-jsco-guidelines"],"cancers":["melanoma","nsclc","gastric","aml"],"sections":["immunotherapy","cell-therapy"],"technologies":["checkpoint-inhibitor","allogeneic-cell-therapy","car-nk-macrophage"],"targets":["pd1","pdl1"],"drugs":["nivolumab"],"companies":["jcog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["akifumi-takaori"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kyoto","country":"JP","lat":35.02,"lng":135.775,"institutionType":"hospital","website":"https://www.kuhp.kyoto-u.ac.jp","university":"Kyoto University","programs":["PD-1 biology and immunotherapy","iPS-derived cell therapy","Haematology","Hepatobiliary-pancreatic surgery"]},"route":"/institutions/kyoto-university-hospital/","neighbours":{"collection":[{"id":"jsmo-jsco-guidelines","kind":"collection","name":"Japanese oncology guidelines (JSMO, JSCO and organ societies)","route":"/collections/jsmo-jsco-guidelines/"}],"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"jcog","kind":"company","name":"Japan Clinical Oncology Group (JCOG)","route":"/companies/jcog/"}],"person":[{"id":"akifumi-takaori","kind":"person","name":"Akifumi Takaori","route":"/people/akifumi-takaori/"},{"id":"tasuku-honjo","kind":"person","name":"Tasuku Honjo","route":"/people/tasuku-honjo/"}]}}